Pdp (68071 4138 03 T70)
Clopidogrel Tablet, Film Coated
Product Images NDC 68071-4138
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 68071-4138). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure-03a.jpg (Figure 03a)
Figure-03b.jpg (Figure 03b)
Figure-06.jpg (Figure 06)
This text contains the results of a clinical trial that evaluated the effectiveness of Clopidogrel compared to Placebo, in patients with Acute Coronary Syndrome. The trial included different subgroups based on gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent given. It reports the number of patients in each subgroup, the percentage of patients who favored Clopidogrel, and the odds ratio. It also lists confidence intervals for the overall results.*
Figure-08.jpg (Figure 08)
This text appears to be a medical study analyzing the effects of the drugs Clopidogrel and Aspirin on patients with qualifying conditions such as stroke, MI, and PAD. The study reports the number of patients favoring each drug and provides hazard ratios for the years 2006 to 2013.*
Structural Formula For Clopidogrel Bisulfate (Image 01)
Figure 1 (Image 02)
Figure 2 (Image 03)
This is a table showing the Cumulative Event Rate of Cardiovascular Death, Myocardial Infarction, and Stroke for a placebo (with aspirin) and Clopdogrel (with aspirin) over several months. Other standard therapies were also used. The P-value is 0.000008. The text also includes some numbers that are likely errors.*
Figure 4 (Image 05)
The text appears to be a table that shows the number of deaths before the first discharge in a study comparing the effectiveness of a placebo versus Clopidogrel. The table shows that out of the total participants, 1845 (3.1%) died with the placebo group and 1726 (7.5%) died in the Clopidogrel group. The table also shows a 7% proportional risk reduction with Clopidogrel in comparison to the placebo, with a p-value of 0.03. The last row of the table shows the timeframe of the study, which was up to 28 days after randomization.*
Figure 5 (Image 06)
This is a statistical data comparison between Placebo and Clopidogrel drugs in terms of their efficacy in reducing death rate, reinfarction, or stroke before the first discharge, measured over a period of 28 days since randomization. The data shows that Clopidogrel has a lower event rate (9.2%) than Placebo (10.1%) and has a 9.7% proportional risk reduction with a p-value of 0.002.*
Figure 8 (Image 09)
This is a chart showing the cumulative event rate for fatal or non-fatal vascular events between the medications Aspirin and Clopidogrel. It shows a significant difference at a p-value of 0.045 over several months of follow-up.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
